Disclosed is a pharmaceutical combination comprising an antibody specifically recognizing CD38 and at least cyclophosphamide , wherein said antibody is capable of killing a CD38+ cell by apoptosis, antibody-dependent cell-mediated cytotoxicity (ADCC), and complement-dependent cytotoxicity (CDC).